CYTOMX THERAPEUTICS I

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

08 May 2024 15:10:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

07 May 2024 15:15:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CYTOMX THERAPEUTICS INC. - COMMON STOCK

01 May 2024 08:45:03 By NetDania Notify

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

01 May 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

08 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

03 Apr 2024 07:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

21 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

18 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

11 Mar 2024 15:10:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CYTOMX THERAPEUTICS INC. - COMMON STOCK

04 Mar 2024 12:12:49 By NetDania Notify

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

04 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CYTOMX THERAPEUTICS INC. - COMMON STOCK

01 Mar 2024 12:17:46 By NetDania Notify

NetDania - New 12 months High: CYTOMX THERAPEUTICS INC. - COMMON STOCK

28 Feb 2024 10:19:37 By NetDania Notify

NetDania - New 12 months High: CYTOMX THERAPEUTICS INC. - COMMON STOCK

27 Feb 2024 11:18:02 By NetDania Notify

CytomX Therapeutics to Present at Upcoming March Investor Conferences

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

24 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

12 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

21 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

07 Nov 2023 15:15:00 By Nasdaq GlobeNewswire